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Human endogenous retroviruses (HERVs), remnants of ancient germ-line infections with
exogenous retroviruses, are estimated to comprise up to 8% of human genome. Most
HERVs have accumulated mutations and deletions that prevent their expression as an
infectious virus. Nevertheless, a growing number of HERV genes and proteins have been
found to be expressed in different cancers, raising the possibility that HERV-derived anti-
gens might represent excellent targets for tumor immunotherapy. Here, we review data
showing HERV-encoded antigens are capable of eliciting humoral andT-cells specific antitu-
mor immunity. We also describe a novel HERV-E that was recently found to be selectively
expressed in over 80% of clear cell kidney cancer but not in normal tissues. Remarkably,
the restricted expression of HERV-E in kidney tumors was found to occur as a consequence
of inactivation of the von Hippel–Lindau tumor suppressor. Importantly, antigens derived
from this provirus are immunogenic, stimulating cytotoxicT-cells that kill kidney cancer cells
in vitro and in vivo. Taken altogether, these data suggest efforts aimed at boosting human
immunity against HERV-derived antigens could be used as a strategy to treat advanced
tumors including kidney cancer.
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INTRODUCTION
The basis for safe and effective adoptive cell therapy is to identify
truly tumor-specific targets to minimize the risk of autoimmu-
nity (1). Many tumor-associated antigens such as the melanoma
antigens gp100 and MART-1 have already established their ability
to induce antitumor T-cell immunity in clinical studies. Patients
with melanoma have also been treated with T-cells engineered
using recombinant retroviral vectors to express HLA-2 restricted
high affinity T-cell receptors specific for these melanoma anti-
gens (2, 3). Since the vast majority of antigens targeted to date are
overexpressed self-antigens, there exists a need to overcome self-
tolerance mechanisms that limit immune responses against these
tumor targets. In contrast, viral antigens are known to induce
strong antitumor immunity due to their foreign nature, although
at present only a minority of human cancers has been shown to
have a viral etiology and to express viral antigens. Over the last
decade, there is a growing list of evidence indicating that human
endogenous retrovirus (HERVs), which under normal conditions
are silenced, can be activated in cancer cells, thus providing a
new source of virus-derived antigens to serve as targets for cancer
immunotherapy.
The vast majority of HERVs have accumulated mutations or
deletions and thus do not contain uninterrupted ORFs to code
full-length proteins, or have had their transcription silenced by
promoter methylation. Nevertheless, a number of different HERVs
have been shown to be transcriptionally active in human malig-
nancies including but not limited to melanoma (4–6), breast
cancer (7), prostate adenocarcinoma (8), ovarian cancer (9, 10),
and most recently renal cell carcinoma (11, 12).
Metastatic kidney cancer appears to be susceptible to immune-
based therapy and allogeneic immunotherapy (13, 14), but sur-
prisingly little data exists characterizing the antigens expressed on
the tumor cells targeted by immune cells that mediate regression
of metastatic renal cancer. Recently, we isolated and expanded
a CD8+ T-cell (CTL) clone from the blood of a patient with
regressing renal cell carcinoma following an allogeneic hematopoi-
etic stem cell transplant that killed patient tumor cells in vitro
(11). This CTL clone was found to have tumor-specific cytotoxi-
city, recognizing an HLA-A11-restricted 10-mer peptide named
CT-RCC-1. The transcripts encoding this antigen were found
to be derived from a novel HERV-E (named CT-RCC HERV-E)
located on chromosome 6q. At present, three transcripts (named
CT-RCC-8, CT-RCC-9, and CT-RCC-Env) originating from this
provirus have been discovered that encode for parts of the protease
and polymerase as well as the entire envelope genes, respec-
tively (GenBank accession numbers EU137846.1, EU137847.1,
and JQ733905). Remarkably, all transcripts derived from the CT-
RCC HERV-E were found to be selectively expressed in the clear
cell variant of renal cell carcinoma (ccRCC), with no expression
observed in normal tissues or any other type of tumor cells (12,
15). Importantly, since proviral expression has been detected in
fresh tumors even at the earliest stages of disease, antigens derived
from CT-RCC HERV-E could theoretically serve as ideal targets
for T-cell based immunotherapy for kidney cancer.
Besides the HERV-E virus described above, which appears to
elicit antitumor immunity against kidney cancer cells, there exists
a growing number of studies showing other endogenous retro-
viral products can induce antitumor immunity in other tumors.
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This review summarizes and critically discusses available data on
HERV-encoded antigens which potentially could serve as targets
for future cancer immunotherapeutic approaches.
HERV REACTIVATION IN CANCER
Human endogenous retroviruses, which represent remnants of
ancient retroviral infections, constitute about 8% of the human
genome. Because approximately 80% of all CpG dinucleotides
are methylated in the genome of differentiated somatic human
cells, proviral LTRs are efficiently silenced by CpG methylation
(16, 17). Abnormal hypomethylation of CpG dinucleotides is a
known characteristic of many cancers. As a consequence, growing
evidence suggests reactivation of HERVs can occur in a variety
of cancers as the result of demethylated LTRs, which function as
promoters, liberating HERV expression (9, 18–22).
Despite the fact that HERVs have been shown to be transcrip-
tionally active in human malignancies, the mechanisms leading to
abnormal cancer-specific activation of HERVs still remain mostly
unclear. Early studies have suggested that expression of ubiqui-
tous transcription factors such as Sp1, Myb, and YY1 proteins
can stimulate transcription of HERVs from hypomethylated LTRs
that contain essential binding sites (23–25). Recent data corrobo-
rated these observations by providing evidence that the HERV-K
promoter activity is dependent on Sp1 and Sp3 transcription fac-
tors (26). Using chromatin immunoprecipitation (ChIP) and RNA
interference assays, the binding of transcription factors Sp1 and
Sp3 to the examined LTR promoter region of HERV-K was shown.
These findings, however, have not revealed the essential mecha-
nism accounting for the restricted expression of HERVs in specific
types of cancer cells.
Other studies have focused on the mechanisms of HERV
transcriptional control indicated the involvement of cell-type-
specific transcription factor in proviral activation. In melanoma,
the arrangement of the TATA-box, binding and initiator sites,
and enhancer sequences in the HERV-K proviral LTR have been
shown to play an important role in the reactivation of the provirus
via binding of melanoma-specific isoform of microphthalmia-
associated transcription factor (MITF-M) to the proviral LTR (27).
In non-melanoma HEK293 cells, both chromosomal HERV-K
expression and the cloned LTR function were strongly activated
by forced expression of MITF-M. The requirement of MITF-
M for the LTR activation seemed to provide a mechanism for
melanoma-specific expression of HERV-K. In addition, expression
of melanocyte-specific genes was also reported in breast cancers
(28), which might also account for HERV-K expression in this
cancer cell type.
Our recent studies have provided insights into the mechanisms
accounting for the restricted expression of a HERV-E in the most
common subtype of renal cell carcinoma, clear cell RCC (12).
Clear cell carcinoma accounts for approximately 80% of all RCC
tumors. In most clear cell cancers, the von Hippel–Lindau (VHL)
tumor suppressor gene is inactivated from either a genetic muta-
tion or promoter hypermethylation. We found that transcriptional
up-regulation of HERV-E in ccRCC is associated with inactiva-
tion of the VHL gene. Using quantitative RT-PCR we found up
to 90% of primary frozen ccRCC tumors obtained from nephrec-
tomy samples from patients whose tumors had VHL mutations
expressed HERV-E transcripts at high levels (in a range of 400 up
to 25,000 copies relative to GAPDH× 105). In addition, expres-
sion of CT-RCC HERV-E was reduced substantially by introducing
wild type VHL transgenes into VHL-deficient ccRCC cell lines. It
has been previously shown that hypoxia-inducible transcription
factors (HIF) are stabilized in a vast majority of ccRCC tumors
as a consequence of VHL inactivation (29). Using a ChIP assay,
we demonstrated that the transcriptional factor HIF-2α plays a
role in promoting expression of HERV-E by binding with a HIF
response element (HRE) localized in its 5′LTR. Remarkably, we
found the HRE motif as well as other surrounding CpGs in the
5′LTR were hypomethylated in all HERV-E expressing ccRCCs.
In contrast, other types of tumors and normal tissues as well
as the small subset of ccRCC cell lines that were found to be
HERV-E negative, possessed a hypermethylated 5′LTR. Consistent
with this observation, we found treating ccRCC cells that con-
tain hypermethylated 5′LTR with the demethylating agent DAC
and/or the histone deacetylase inhibitor depsipeptide increased
HERV-E expression. In summary, these findings show the tran-
scriptional up-regulation of HERV-E in ccRCC appears to be
related to three critical events: (i) VHL inactivation, (ii) HIF-2α
overexpression, and (iii) hypomethylation of the HERV-E 5′LTR
(Figure 1).
The presence of multiple binding sites in retroviral LTRs con-
tributes to the complexity and flexibility of HERV transcriptional
activation. Additional studies are necessary to further reveal the
exact cellular transcriptional regulatory mechanisms that allow
cancer-specific expression of HERV loci in different types of
tumors.
SEROLOGICAL RESPONSE TO HERVs IN CANCER
Although most HERVs have extensive deletions and mutations
that render them inactive, some have retained ORFs coding for full
or partial proteins that potentially can be translated if the provirus
is reactivated. For example, HERV-K, the youngest HERV from
an evolutionary perspective, in some cases contains nearly intact
ORFs with a few or even no mutations (30–32). The first studies
that aimed to investigate a potential patho-physiological role of
HERV-K revealed the presence of HERV-K specific antibodies in
patients with germ cell tumors (33, 34). Sequences of intact gag
and env ORFs in the HERV-K10 provirus were incorporated into
a baculovirus vector; subsequently the recombinant proteins were
then utilized to screen human serum for antibody reactivity by
employing immunofluorescence. These studies revealed patients
with seminoma or mixed germ cell tumors produced antibodies
against Gag or Env proteins at a very high frequency. In contrast,
healthy individuals and patients with different types of tumors
rarely produced these antibodies.
In addition to these findings, a high prevalence of antibod-
ies against HERV-K proteins was also found in the serum of
patients with melanoma. Of note, the level of antibodies against
HERV-K Env was shown to be significantly higher in sera from
melanoma patients compared to that of normal blood donors (5,
35). Data from subsequent studies reported antibody responses
against HERV-K proteins in melanoma patients was associated
with poorer survival, and thus could potentially be used as a disease
specific prognostic factor (36).
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FIGURE 1 |Transcriptional up-regulation of CT-RCC HERV-E in clear cell RCC appears to be a consequence of three events: (i)VHL inactivation, (ii)
HIF-2α overexpression, and (iii) hypomethylation of the HERV-E 5′LTR.
More recently, various studies have demonstrated that HERV-K
is reactivated in the majority of human breast tumors. Significant
titers of anti-HERV-K antibodies were detected in a high propor-
tion of patients with breast cancer, but not in the serum of normal
donors (37–39). Preclinical data further suggest proteins prod-
ucts of HERV-K could potentially serve as targets for antibody
based treatments for breast cancer. In one study, immunodefi-
cient mice were injected with human breast cancer cells and then
subsequently infused with anti-HERV-K Env monoclonal anti-
bodies (mAbs), which markedly reduced tumor development (40).
In vitro results from this study showed anti-HERV-K Env mAb
blocked both the growth and proliferation of human breast cancer
cells.
Interestingly, in contrast to most cancers, three different
HERV families (HERV-K, HERV-E, and ERV3) were found to
be expressed in ovarian cancer (10). Remarkably, antibodies
against HERV Env proteins, including anti-ERV3 (30%), anti-
HERV-E (40%), and anti-HERV-K (55%), were detected in the
serum of patients with ovarian cancer, but not in healthy con-
trols. Taken altogether, these findings illustrate that expression
of HERVs in cancer cells may trigger antigen-specific immune
responses. Based on preclinical animal experiments, these data
suggest mAbs targeting HERV antigens could potentially be used
as novel immunotherapeutic agents.
CTL RECOGNITION OF HERV ANTIGENS
In a variety of tumors, the immunogenicity of HERV-originated
proteins or peptides has been assessed by their ability to elicit
CTL-mediated immune recognition. For example, in melanoma,
HERV-encoded peptides expressed in the tumor have been shown
to trigger antitumor CTL responses (41). A HERV-K-encoded
HLA-A2-restricted peptide (termed HERV-K-Mel) that was rec-
ognized by CTLs on autologous tumor cells of a melanoma patient
was identified utilizing a cDNA expression cloning. This peptide
was found to originate from a very short ORF from a HML-6
provirus located on chromosome 16 encoding a HERV-K-MEL
env transcript. This observation highlights the fact that antigenic
peptides can be translated from small alternative ORFs within
retroviral transcripts, even when a main ORF encoding for a
retroviral protein is absent as a consequence of mutations. HERV-
K-MEL was not found to be expressed in normal tissues, with the
exception of testis, but was found in nearly 85% of melanoma
samples. Besides melanoma, most tumor types did not express the
HERV-K-MEL, apart from a few sarcoma and carcinoma samples
which only rarely expressed this transcript. These observations
suggest HERV-K-MEL may be a useful source of tumor-specific
antigens that could be used for therapeutic vaccination for the
majority of patients with melanoma as well as a small proportion
of patients with carcinoma.
In other studies, CTLs against HERV-K Gag-derived peptides
have been detected in patients with seminoma tumors (42). Based
on previous reports that demonstrated an antibody response spe-
cific to the Gag protein of HERV-K10 (33), seminoma patients
were screened for T-cell responses specific for HERV-K Gag pro-
tein derived peptides. Twenty-six subjects with a history of semi-
noma were recruited for this study and all met the following
criteria: the seminoma had been cured with orchiectomy, followed
by radiation therapy within 1 month of diagnosis, and showed no
recurrence or metastases. Eighteen healthy donors with no his-
tory of germ cell tumors were also used in this study. The time
range from treatment of the cancer to the blood donation for
detection of anti-HERV T-cell responses varied from 6 months
to 25 years. Four peptide pools representing potential epitopes of
the Gag protein were used for an initial screening to detect T-
cell responses in the patients that were previously diagnosed with
seminoma. The pools consisted of peptides that were predicted to
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have a high binding affinity for relatively common HLA alleles.
Remarkably, T-cells reactive to the HERV-K peptide pools were
found in the PBMCs of seminoma patients at a much higher fre-
quency compared to healthy controls where T-cell responses were
rarely seen.
Just as HERV specific T-cells were observed in melanoma and
seminoma patients, the ability of HERV-H Xp22.3 envelope pep-
tides to induce strong tumor-specific T-cell responses was shown
to occur in patients with gastrointestinal cancer (43). Previous
studies found that HERV-H Xp22.3 env mRNA was expressed in
gastrointestinal cancer, but not in other cancers or normal tis-
sues (20). As a result, peptides predicted to bind to HLA-A∗0201
derived from a putative 273 aa protein encoded from HERV-H
Xp22.3 env ORF were used to stimulate peripheral blood T-cells
to generate peptide specific CTLs (43). Remarkably, these CTLs
induced tumor-specific lysis of gastrointestinal cancer cell lines
that endogenously expressed the HERV-H Xp22.3 env ORF. Taken
altogether, these findings demonstrate that the Env protein is syn-
thesized, processed by proteasomal pathways, and presented in the
context of HLA-A2.1 on the cancer cell surface.
In our laboratory, we isolated and expanded a CTL clone from
the blood of a patient with regressing renal cell carcinoma follow-
ing an allogeneic stem cell transplant that killed patient tumor
cells in vitro (11). This CTL clone was found to have tumor-
specific cytotoxicity, recognizing an HLA-A11-restricted antigen
called CT-RCC-1 that originated from CT-RCC HERV-E. Because
only about 15–18% of the human population possesses HLA-
A11, immunotherapy approaches targeting the CT-RCC-1 antigen
through tumor peptide vaccination would be limited to only a
minority of patients with metastatic kidney cancer. However, it
is possible that other immunogenic peptides derived from this
HERV-E could be expressed on more common HLA class I mol-
ecules, a finding that potentially could broaden the application
of immunotherapy approaches targeting antigens derived from
this HERV to a greater percentage of patients with metastatic
RCC. Most recently, we have observed transcripts encoding for
the entire env gene of CT-RCC HERV-E that are also selectively
expressed in a majority of ccRCC tumors, concurrent with two pre-
viously identified transcripts, with no expression observed in any
other tumors or normal tissues (15). Analysis of the envelope tran-
script’s encoding capacities showed long ORFs potentially leading
to translation of surface (SU) and transmembrane (TM) envelope
proteins. Using a similar approach as was done with the HERV-
H Xp22.3 Env, we generated HERV-E Env peptides derived from
the SU and TM ORFs that were predicted to have a high bind-
ing affinity for HLA-A∗0201. Monocyte derived dendritic cells of
healthy HLA-A∗0201+ donors were pulsed with these peptides
to stimulate autologous T-cells in vitro. Several of these pep-
tides were found to be immunogenic in vitro, stimulating CTLs
that recognized HERV-E expressing ccRCC tumor cells trans-
fected to express HLA-A∗0201, but not wild type ccRCC that was
HERV-E+/HLA-A∗0201-negative (15). Since CT-RCC HERV-E
sequences are not expressed in normal tissues, tolerance induc-
tion by T-cells, which would normally occur against self-antigens,
would theoretically be less likely to occur. Therefore, CT-RCC Env
antigens, when expressed in a newly formed ccRCC tumor, could
represent excellent potential targets for T-cell based immunother-
apy for kidney cancer. However, at present, the ability of the human
immune system to recognize these HERV-E derived antigens has
not been fully analyzed nor has the proposal that that avoidance
of tolerance induction to these apparently tumor-specific antigens
been tested experimentally. Despite these limitations, preliminary
data suggest, the field of cancer immunotherapy could potentially
be advanced by the identification of additional antigens derived
from HERVs that are specifically expressed in tumor cells and are
recognized by CTLs.
CONCLUSION
Cancer remains a significant problem worldwide. Expression of
potentially immunogenic HERV proteins that behave as tumor-
associated antigens have been detected by a growing number of
independent investigators in a variety of different types of tumors
over the last decade. Similar to antiviral vaccines now used to
prevent cervical cancer (anti-HPV vaccine) or hepatocellular car-
cinoma (anti-hepatitis B vaccine), vaccines against HERV antigens
that are typically not expressed in normal tissues could stimu-
late long lasting CTL responses which might prevent or eradicate
malignancies at their earliest stages or more advanced cancers
where metastasis express proviral antigens. The capacity of HERVs
to produce full or partial length proteins in different cancers
and their capability to induce cellular and/or humoral immune
responses in the host remains an exciting and open area of inves-
tigation which holds great therapeutic promise for the prevention
and treatment of cancer.
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